Browse FASLG

Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein Cytoplasmic vesicle lumen Lysosome lumen Note=Is internalized into multivesicular bodies of secretory lysosomes after phosphorylation by FGR and monoubiquitination (PubMed:17164290). Colocalizes with the SPPL2A protease at the cell membrane (PubMed:17557115). ; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 6, soluble form: Secreted Note=May be released into the extracellular fluid by cleavage from the cell surface. ; SUBCELLULAR LOCATION: FasL intracellular domain: Nucleus Note=The FasL ICD cytoplasmic form is translocated into the nucleus.
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells (PubMed:26334989, PubMed:9228058). Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development (PubMed:9228058, PubMed:7528780, PubMed:9427603). Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses (By similarity). TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance (By similarity). Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis (PubMed:27806260). ; FUNCTION: Tumor necrosis factor ligand superfamily member 6, soluble form: Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways (By similarity). Can induce apoptosis but does not appear to be essential for this process (PubMed:27806260). ; FUNCTION: FasL intracellular domain: Cytoplasmic form induces gene transcription inhibition.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001654 eye development
GO:0002237 response to molecule of bacterial origin
GO:0006885 regulation of pH
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0006925 inflammatory cell apoptotic process
GO:0007032 endosome organization
GO:0007033 vacuole organization
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007423 sensory organ development
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0010623 programmed cell death involved in cell development
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016525 negative regulation of angiogenesis
GO:0030002 cellular anion homeostasis
GO:0030004 cellular monovalent inorganic cation homeostasis
GO:0030320 cellular monovalent inorganic anion homeostasis
GO:0030641 regulation of cellular pH
GO:0030644 cellular chloride ion homeostasis
GO:0032496 response to lipopolysaccharide
GO:0038127 ERBB signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045765 regulation of angiogenesis
GO:0045851 pH reduction
GO:0045862 positive regulation of proteolysis
GO:0046666 retinal cell programmed cell death
GO:0048388 endosomal lumen acidification
GO:0048514 blood vessel morphogenesis
GO:0048592 eye morphogenesis
GO:0051402 neuron apoptotic process
GO:0051452 intracellular pH reduction
GO:0051453 regulation of intracellular pH
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055064 chloride ion homeostasis
GO:0055067 monovalent inorganic cation homeostasis
GO:0055081 anion homeostasis
GO:0055083 monovalent inorganic anion homeostasis
GO:0070227 lymphocyte apoptotic process
GO:0070231 T cell apoptotic process
GO:0070265 necrotic cell death
GO:0070266 necroptotic process
GO:0070997 neuron death
GO:0071887 leukocyte apoptotic process
GO:0072577 endothelial cell apoptotic process
GO:0090596 sensory organ morphogenesis
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097296 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:0097300 programmed necrotic cell death
GO:0097527 necroptotic signaling pathway
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000353 positive regulation of endothelial cell apoptotic process
GO:2001056 positive regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:2001269 positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function GO:0005123 death receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component GO:0005775 vacuolar lumen
GO:0005901 caveola
GO:0009897 external side of plasma membrane
GO:0031983 vesicle lumen
GO:0043202 lysosomal lumen
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0098552 side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04068 FoxO signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04650 Natural killer cell mediated cytotoxicity
hsa04722 Neurotrophin signaling pathway
Reactome R-HSA-109581: Apoptosis
R-HSA-5218900: CASP8 activity is inhibited
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-73887: Death Receptor Signalling
R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-69416: Dimerization of procaspase-8
R-HSA-1643685: Disease
R-HSA-75157: FasL/ CD95L signaling
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-140534: Ligand-dependent caspase activation
R-HSA-8863678: Neurodegenerative Diseases
R-HSA-5357801: Programmed Cell Death
R-HSA-5213460: RIPK1-mediated regulated necrosis
R-HSA-5218859: Regulated Necrosis
R-HSA-3371378: Regulation by c-FLIP
R-HSA-5675482: Regulation of necroptotic cell death
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FASLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FASLG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28131992Pancreatic CarcinomaPromote immunity (infiltration)The Fas-FasL/CTLs and the MLL1-H3K4me3-PD-L1 axis play contrasting roles in pancreatic cancer immune surveillance and evasion.
25545618Breast CarcinomaPromote immunityActivated TDLN B cells express Fas ligand, which was further enhanced by coculture of these TDLN B cells with 4T1 tumor cells.
18386791Lung CarcinomaPromote immunity (T cell function); essential for immunotherapyCombination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. In addition, IL-12 production, cytotoxic T-cell activity and IgG against LLC-1 are manifested in mice injected with LLC/FasL/GM-CSF. Taken together, the results indicate that dual gene-based delivery with FasL and GM-CSF may serve as a more effective tumor vaccine to suppress lung cancer cell growth in vivo.
19223535MelanomaPromote immunityFas ligand (FasL) is a transmembrane protein that induces apoptosis in cells expressing its receptor, Fas. When grafted into mice, FasL-expressing tumor cells break immunologic tolerance to self-antigens and induce antibody-mediated tumor immunity.
23530146LymphomaPromote immunity (T cell function)Previously, we found that adiponectin (APN) suppresses IL-2-induced NK cell activation by downregulating the expression of the IFN-γ-inducible TNF-related apoptosis-inducing ligand and Fas ligand. In this study, we assessed the role of APN in immune cell function, including NK cells, CTLs, and myeloid-derived suppressor cells, in EL4 and B16F10 tumor-bearing APN knockout (KO) mice. In APNKO mice, splenic NK cells showed enhanced cytotoxicity with and without IL-2 stimulation.
19692638Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function)Sera of patients with cancer contain membraneous microvesicles (MV) able to induce apoptosis of activated T cells by activating the Fas/Fas ligand pathway.
19654302Renal Cell CarcinomaPromote immunity (T cell function)The biological relevance of the perforin and Fas ligand (FasL) cytolytic pathways of CD8(+) T lymphocytes (CTL) for cancer immunotherapy is controversial. Blocking FasL in vivo inhibited tumor rejection in these mice. Strikingly, a range of mouse tumor cells presenting low concentrations of immunogenic peptide were all preferentially lysed by the FasL but not the Pfp-mediated effector pathway of CTL, whereas at higher peptide concentrations, the preference in effector pathway usage by CTL was lost. Therefore, the FasL cytolytic pathway may be particularly important for eradicating Fas-sensitive tumors presenting low levels of MHC class I-associated antigens following adoptive T-cell therapy.
16767155LymphomaPromote immunity (T cell function)CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4+ CD8+ double positive thymic lymphoma.
27535994Chronic Lymphocytic LeukemiaPromote immunity (T cell function); increase the efficacy of immunotherapyWe identified the immunoglobulin M Fc receptor (FcμR), also known as the Fas apoptotic inhibitory molecule-3 or TOSO, as a target for a more selective treatment of CLL by CAR T cells. FcμR is highly and consistently expressed by CLL cells; only minor levels are detected on healthy B cells or other hematopoietic cells. T cells with a CAR specific for FcμR efficiently responded toward CLL cells, released a panel of proinflammatory cytokines and lytic factors, like soluble FasL and granzyme B, and eliminated the leukemic cells. In contrast to CD19 CAR T cells, anti-FcμR CAR T cells did not attack healthy B cells.
24793239Ovarian CarcinomaInhibit immunity (infiltration and cell function)In these tumors, FasL expression was associated with scarce CD8(+) infiltration and a predominance of FoxP3(+) T regulatory (Treg) cells. Tumor-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expression in endothelial cells, which acquired the ability to kill effector CD8(+) T cells but not Treg cells because of higher levels of c-FLIP expression in Treg cells. In mice, genetic or pharmacologic suppression of FasL produced a substantial increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells. Pharmacologic inhibition of VEGF and PGE2 produced a marked increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells that was dependent on attenuation of FasL expression and led to CD8-dependent tumor growth suppression.
27853178Hepatocellular CarcinomaPromote immunityEnvironmental semimature dendritic cells, but not macrophages, can operate in a CD95L-dependent pathway to generate FcγRIIlow/- activated B cells.
20145137Breast CarcinomaPromote immunity (T cell function)In allogeneic MLTR, antiestrogen-treated MCF-7 cells caused downregulation of the effector molecules granzyme B, perforin, and Fas ligand in CD8(+) T cells, and suppressed the generation of cytotoxic effector cells in a TGFbeta-dependent manner.
15981207Cervical CarcinomaPromote immunity (T cell function)Our results demonstrated that chimeric CRT/E7 DNA vaccine resulted in control of tumors with downregulated Fas expression, highlighting the importance of the Fas-FasL pathway in the potent antitumor effect of antigen-specific CD8+ cytotoxic T lymphocytes and the role of Fas as part of in vivo tumor evasion.
15940614Colorectal CancinomaInhibit immunity (T cell function)These data show that colorectal cancer induces T-cell apoptosis through the release of Fas ligand-bearing and tumor necrosis factor-related apoptosis-inducing ligand-bearing microvesicles both in vitro and in vivo.
20406899GliomaInhibit immunity (infiltration)Here, we show that FasL expression can support the growth of experimental intracranial glioma. FasL was found to be expressed by three well-characterized rat glioma cell lines (9L, F98, and C6) and glioma cell-derived FasL mediated the death of phytohemagglutinin-stimulated Jurkat T-lymphocytes when cocultured with glioma cells in vitro. FasL expression knockdown using shRNA reduced the growth of subcutaneous and intracranial 9L gliomas by approximately 50% in immune competent Fisher 344 rats. These results demonstrate that down-regulating FasL expression and/or function in glial malignancies can enhance T-cell tumor infiltration and inhibit tumor growth.
20233867Breast CarcinomaPromote immunityIntratumoral administration of anti-FasL antibody promoted tumor growth. The decrease in Tregs (Fas(+)) was due to apoptosis induced by cell contact with Fas ligand(+) (L)(+) Th.
17510409AdenomaPromote immunity (infiltration)Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Comparison of FasL-deficient versus proficient Min mice revealed a significant increase in polyp number in the gld/gld mice. Although the Fas counterattack hypothesis suggests that the absence of FasL would result in increased immune-mediated tumor elimination, the opposite is true in the Min model with lack of functional FasL associated with reduced neutrophil influx and increased tumor development.
16267003Colon CarcinomaInhibit immunity (infiltration)Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Down-regulation of FasL expression had no effect on tumor growth in vitro but significantly reduced tumor development in syngeneic immunocompetent mice in vivo. Reduced FasL expression by tumor cells led to increased lymphocyte infiltration.
25248763lymphomaPromote immunity (T cell function)Bone marrow chimeras revealed that IFNgammaR1 and Fas expression on immune cells was most critical for rejection, and SPLNX increased the frequency of activated macrophages (Mvarphi) within intraocular tumors in an IFNgamma- and Fas/FasL-dependent manner, suggesting an immune cell target of IFNgamma and Fas. As depletion of Mvarphis limited CD8 T cell-mediated rejection of intraocular tumors in SPLNX mice, our data support a model in which IFNgamma- and Fas/FasL-dependent activation of intratumoral Mvarphis by CD8(+) T cells promotes severe intraocular inflammation that indirectly eliminates intraocular tumors by inducing phthisis, and suggests that immunosuppressive mechanisms that maintain ocular IP interfere with the interaction between CD8(+) T cells and Mvarphis to limit the immunosurveillance of intraocular tumors.
25092771colon carcinomaPromote immunityThis combination therapy also increased TILs, including tumor antigen-specific CD8 T cells, and elevated the expression of activation markers FAS-L, CXCL-9, CD31, and CD105 in MDSCs and TAMs, leading to reduced tumor volumes and an increase in the number of tumor-free animals.
23341634fibrosarcoma; MelanomaPromote immunityComplete tumor rejection required IFNgamma-regulated Fas by the tumor stroma. Therefore, T(E) cells lacking IFNgamma or FasL cannot prevent progression of antigenic cancer because the tumor stroma escapes destruction if its Fas expression is down-regulated.
11875499colon carcinomaPromote immunityCTL and NK cells promote tumor cell apoptosis with delivery of perforin and granzymes directly into cells or through the extrinsic pathway, inducing apoptotic death by triggering death receptors by the TNF family of molecules, including TRAIL, TNF- , Fas ligand (FasL), and lymphotoxin (LT), thereby inducing apoptosis in cells.
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FASLG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FASLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4070.292
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3670.591
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4310.434
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5960.144
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6110.479
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5850.592
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9280.154
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.770.0602
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0260.979
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0010.0339
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7090.221
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4020.098
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FASLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FASLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FASLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FASLG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FASLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FASLG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FASLG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFASLG
NameFas ligand (TNF superfamily, member 6)
Aliases FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FASLG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.